Efficacy and safety of non‐cross‐linked hyaluronic acid compound in the treatment of keratosis pilaris: A split‐body randomized clinical trial

This study evaluated the efficacy and safety of a non-cross-linked hyaluronic acid (HA) compound for treating keratosis pilaris (KP) through a split-body, randomized clinical trial. The treatment involved injecting the HA compound into KP-affected areas on the upper arms over four sessions. Results showed significant improvements in skin roughness and overall scores for treated areas compared to controls, with 71.43% of patients reporting persistent improvements in roughness at 24 weeks post-treatment. Both physician and patient assessments indicated reductions in roughness and redness, supported by dermatoscopic and histopathological improvements. The study concludes that the non-cross-linked HA compound is an effective and safe treatment for KP, offering a promising alternative therapy in clinical practice.